The global cluster headache treatment market is estimated to grow at a CAGR of around 6% during the forecast period. The major factors contributing to the growth of the market include the growing geriatric population and the increasing number of cases of cluster headache syndrome. Additionally, increase in the usage of computers, laptops, and smartphones for personal as well as professional purposes among people rising the cases of cluster headache syndrome, hence increasing the demand for drugs and devices for pain management. According to World Health Organization (WHO) report, one in thousand adults is suffering from cluster headache and it is more prone to affect men as compared to women, affecting around six men to each woman. 

Rising demand for cluster headache disorder solutions and the availability of skilled professionals in hospitals and clinics are key attributes leading to the increasing growth of the cluster headache treatment market. Moreover, the increasing number of multi-specialty hospitals in developed and developing countries and growing awareness among people toward health are further strengthening the cluster headache treatment market. New developments and technological advancements in the healthcare sector propelling the growth of the cluster headache treatment market. For instance, in June 2019, the US Food and Drug Administration (FDA) announced the approval of the Emgality (galcanezumab) solution for injection that is designed with the aim of treatment of episodic headache in adults. The approval is granted to Eli Lilly by the FDA for the better treatment of cluster headache. The drug reduces the frequency of attacks of episodic cluster headache.

Segmentation

The global cluster headache treatment market is segmented based on drugs and devices. Based on drug type, the market is classified into triptans, octreotide, dihydroergotamine, and others. The continuous efforts to develop innovative devices for managing cluster headache is driving the growth of the device segment. For instance, in November 2018, ElectroCore, Inc. received FDA approval for an expanded label for gammaCore [non-invasive vagus nerve stimulator (nVNS)] therapy for adjunctive use for the preventive treatment of cluster headache in adult patients. However, the drug segment held the highest market share owing to the easy availability and comparatively low cost than nerve stimulators. The drugs are available at hospital clinics, private clinics, and retail pharmacies.

Regional Outlook

Geographically, the global cluster headache treatment market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. Asia-Pacific is estimated to witness significant growth in the market owing to the significant prevalence of the geriatric population and rising incidences of cluster headache syndrome in the region. Increasing healthcare expenditure, technological advancement in the healthcare sector, and the increasing number of multi-specialty hospitals and private clinics are further strengthening the market growth in the region. Moreover, the major companies are expanding their presence in these regions, which in turn, will likely contribute to the significant growth of the cluster headache treatment market in the region.

Global Cluster headache treatment market Growth, by Region 2019-2025

North America dominates the cluster headache treatment market. 

North America to witness major share in the market owing to the presence of major companies such as ElectroCare Medical LLC, GlaxoSmithKline plc, Winston Pharmaceuticals, and AstraZeneca PLC. These companies have captured a major share in the cluster headache treatment market in the region. These companies are significantly focusing on marketing their products across the globe and gain a competitive advantage. Additionally, a wide-ranging cluster headache drugs and injection solutions offered by these companies are supporting to attract a significant number of end-users towards their medical services, which in turn, is contributing to huge revenue generation from North America. Government expenditure on health care is also supporting the growth of the cluster headache treatment market.

Competitive Landscape

The major companies in the cluster headache treatment market include AstraZeneca PLC, Aurobindo Pharma, Ltd., Dr. Reddy's Laboratories, Ltd., ElectroCore Medical LLC, Eli Lilly and Company, Fresenius Kabi Pharmaceuticals Holding, Inc., GlaxoSmithKline PLC, Merck KGaA, Mylan N.V., Novartis AG, and Ranbaxy Laboratories, Ltd. The strategies followed by the market players include mergers and acquisitions, partnerships and collaborations and geographical expansion to expand market share across the globe. 

The Report Covers

• Market value data analysis of 2018 and forecast to 2025.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global cluster headache treatment market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.